Effects of preoperative quadruple therapy for helicobacter pylori on bariatric surgery metabolic outcomes

Purpose: To assess the effects of Helicobacter pylori (HP) eradication with an omeprazole, clarithromycin, amoxicillin, and metronidazole (OCAM) regimen on the metabolic profile and weight loss 12 months after bariatric surgery (BS). Methods: Retrospective analysis of a prospective cohort of patient...

Descripción completa

Detalles Bibliográficos
Autores: Goday Arnó, Albert, Bagán, Andrea, Casajoana, Anna, Serra, Carme, Pera Román, Manuel, Villatoro Moreno, Montserrat, Legido, Teresa, Julià, Helena, Climent, Elisenda, Castañer, Olga, Flores Le Roux, Juana Antonia, Olano, Miguel, Pedro-Botet, Juan, Benaiges Foix, David
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Universitat Pompeu Fabra
Repositorio:Repositorio Digital de la UPF
OAI Identifier:oai:repositori.upf.edu:10230/68404
Acceso en línea:http://hdl.handle.net/10230/68404
http://dx.doi.org/10.1007/s11695-024-07091-x
Access Level:acceso abierto
Palabra clave:Helicobacter pylori
Bariatric surgery
Gastric bypass
Morbid obesity
Sleeve gastrectomy
Descripción
Sumario:Purpose: To assess the effects of Helicobacter pylori (HP) eradication with an omeprazole, clarithromycin, amoxicillin, and metronidazole (OCAM) regimen on the metabolic profile and weight loss 12 months after bariatric surgery (BS). Methods: Retrospective analysis of a prospective cohort of patients with morbid obesity undergoing BS. HP presence was tested preoperatively by gastric biopsy and treated with OCAM when positive. Short-term metabolic outcomes and weight loss were evaluated. Results: HP infection was detected in 75 (45.7%) of the 164 patients included. OCAM effectiveness was 90.1%. HP-negative patients had a greater reduction in glucose levels at 3 (-14.6 ± 27.5 mg/dL HP-treated vs -22.0 ± 37.1 mg/dL HP-negative, p=0.045) and 6 months (-13.7 ± 29.4 mg/dL HP-treated vs -26.4 ± 42.6 mg/dL HP-negative, p= 0.021) and greater total weight loss (%TWL) at 6 (28.7 ± 6.7% HP-treated vs 30.45 ± 6.48% HP-negative, p= 0.04) and 12 months (32.21 ± 8.11% HP-treated vs 35.14 ± 8.63% HP-negative, p= 0.023). Conclusions: Preoperative treatment with OCAM has been associated to poorer glycemic and weight loss outcomes after BS. More research is needed on the influence of OCAM on gut microbiota, and in turn, the effect of the latter on metabolic and weight loss outcomes after BS.

Similares en LA Referencia